This filing is routine — the equity plan increase is standard for employee retention and does not signal a capital raise. Monitor future S-8 filings or 10-Q for actual share issuance under the plan. The proxy contest context (DEFA14A filed May 22) appears resolved with all management-backed directors elected.
Price Chart
Executive Summary
Pacific Biosciences (PACB) filed an 8-K reporting that shareholders approved an amendment to the 2020 Equity Incentive Plan, adding 16,000,000 shares of common stock for future equity grants. The annual meeting also saw the election of six Class III directors and ratification of Ernst & Young as auditor. This is a routine administrative filing with no material financial impact.
Key Facts
- Shareholders approved an amendment to the 2020 Equity Incentive Plan, adding 16,000,000 shares of common stock for issuance.
- Annual meeting held June 3, 2026; ~65% of outstanding shares (203,009,375 of 310,487,099) were represented.
- All six Class III director nominees were elected with strong support (128M–131M votes 'for' each).
- Ernst & Young LLP was ratified as independent auditor for FY2026 (198M 'for', 3.99M 'against').
- Non-binding advisory vote on named executive officer compensation passed (114M 'for', 21.2M 'against').
- The equity plan amendment passed with 114.9M 'for', 20.5M 'against', and 1.9M abstentions.
- No officer departures, no financial results, and no material corporate events reported.
Financial Impact
16,000,000 additional shares authorized for equity grants; no immediate dilution as shares are not yet issued.
Risk Factors
- Potential future dilution if all 16M shares are granted and vest, though this is typical for a company of PACB's size.
- The 21.2M 'against' votes on say-on-pay (15.5% of votes cast) indicate some shareholder discontent with executive compensation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001299130-26-000092 |
| Document: pacb-20260603.htm | 0001299130-26-000092 |
| Document: 0001299130-26-000092-index-headers.html | 0001299130-26-000092 |
| Document: 0001299130-26-000092-index.html | 0001299130-26-000092 |
| Document: 0001299130-26-000092.txt | 0001299130-26-000092 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $1.84 | awaiting T+5 | — | $2.25 (+22.28%) |
Oct 6, 2026 19d ago | 144 | $2.72 $1.99 | ▲ +26.84% | ▲ +25.86% | $2.25 (+17.28%) |
Oct 6, 2026 20d ago | Press Release | $2.70 $2.05 | ▼ −24.07% | ▼ −23.94% | $2.25 (−16.67%) |
Jun 4, 2026 20w ago | 8-K | $1.45 $1.31 | ▼ −9.66% | ▼ −10.22% | $2.25 (+55.17%) |
May 22, 2026 22w ago | DEFA14A | $1.26 $1.58 | ▲ +25.40% | ▲ +24.31% | $2.25 (+78.57%) |
Apr 21, 2026 26w ago | Press Release | $1.73 $1.58 | ▼ −8.67% | ▼ −9.75% | $2.25 (+30.06%) |
Apr 16, 2026 27w ago | Press Release | $1.69 $1.56 | ▼ −7.69% | ▼ −8.25% | $2.25 (+33.14%) |
Mar 5, 2026 33w ago | 8-K | $1.52 $1.27 | ▼ −16.45% | ▼ −14.21% | $2.25 (+48.03%) |
Mar 3, 2026 33w ago | Insider Cluster | $1.52 $1.37 | ▼ −9.87% | ▼ −9.39% | $2.25 (+48.03%) |
Feb 28, 2026 34w ago | Institutional Cluster | $1.62 $1.39 | ▼ −14.20% | ▼ −12.99% | $2.25 (+38.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers